Cathay Biotech Inc. (SHA:688065)

Market Cap	39.07B +80.7%
Revenue (ttm)	3.29B +19.0%
Net Income	594.46M +49.4%
EPS	0.92 +34.9%
Shares Out	720.66M
PE Ratio	59.07
Forward PE	59.57
Dividend	0.40 (0.74%)
Ex-Dividend Date	Aug 1, 2025

Volume	3,903,659
Average Volume	8,052,561
Open	54.17
Previous Close	54.40
Day's Range	53.23 - 55.12
52-Week Range	41.88 - 64.50
Beta	0.76
RSI	46.49
Earnings Date	Apr 24, 2026

About Cathay Biotech

Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for electrification, automation, and digitization for biological manufacturing. The company’s products are used in textiles, pharmaceuticals, perfumes, aut...

• Industry: Chemicals
• Sector: Materials
• Founded: 2000
• Employees: 1,764
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688065

Financial Performance

In 2024, Cathay Biotech's revenue was 2.96 billion, an increase of 39.91% compared to the previous year's 2.11 billion. Earnings were 488.96 million, an increase of 33.41%.